BioSpace News Archive

SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce its autumn conference schedule for September and October.

Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to its New Drug Application (NDA) for rezafungin for the treatment of candidemia and invasive candidiasis.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced CEO Jeff Ross will present at the Bioregate European Regenerative Medicine Forum.

OraSure Technologies, Inc. announced that the Company has been selected to provide its OraQuick® In-Home HIV tests in support of the Centers for Disease Control and Preventions “Together Take Me Home,” HIV self-test program.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM).

According to Nova one advisor, the global Multiplex Assays market was valued at USD 3.4 billion in 2021 and it is expected to hit around USD 6.3 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be participating in the Lytham Partners Fall 2022 Investor Conference, taking place virtually on September 28-29, 2022.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares.